NCT03529955View on ClinicalTrials.gov

Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

February 28, 2021

Study Completion Date

April 7, 2021

Conditions
Dermatomyositis, Adult Type
Interventions
DRUG

Apremilast 30mg

Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).

Trial Locations (1)

70112

Tulane University, New Orleans

All Listed Sponsors
lead

Tulane University

OTHER

NCT03529955 - Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis | Biotech Hunter | Biotech Hunter